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Objectives: Many centres preferentially use polytetrafluoroethylene (PTFE) for above-knee f moropopliteal bypass as 
surgery is simplified and patency rates are comparable to vein, which is preserved for subsequent revisions or for distal 
disease progression. In this Unit, vein remains first choice graft material. The aim of this study was to audit our results 
with respect o above-knee bypass to establish the demand for vein for secondary reconstruction and to document he 
ultimate fate of the limb. 
Patients- Between 1983 and 1992, 112 above-knee r constructions were performed on 109 patients (89 vein and 23 PTFE 
grafts). PTFE was used where vein was absent or inadequate. Life table analysis of primary graft patency, limb salvage and 
patient survival up to 36 months follow-up concurs with previously reported series. 
Results- Twenty-eight vein grafts (31%) and 11 PTFE grafts (48%) occluded uring a median follow-up of 64 months 
(8-116 months). In only four cases was vein required for secondary procedures. The remainder were salvaged by 
thrombectomy and local procedures for technical problems. Amputation rates following graft occlusion were 12% in the 
vein group (20% of these being above-knee) asagainst 26% in the PTFE group (80% above knee). 
Conclusions: The demand for vein for secondary procedures i low. Amputation rates when vein grafts do occlude are half 
those of PTFE and amputation level is significantly influenced by graft type. We advocate preferential use of vein in above- 
knee femoropopliteal bypass. 
Introduction 
Bypass grafting for occlusive vascular disease is an 
established treatment option. Whilst prosthetic ma- 
terials are suitable for replacement of large-calibre 
vessels, autogenous vein is preferred for bypass below 
the inguinal ligament and is the definitive method 
against which all other materials are compared. 1 
Inadequacy or absence of vein demands an alternative 
conduit. Following the introduction of polytetra- 
fluoroethylene (PTFE) in 1976, 2numerous preliminary 
studies reported optimistic early results, some claim- 
ing equivalent performance with saphenous vein, 
particularly above the knee and in claudicants. 3~ 
However, initial optimism has been tempered by the 
emergence of less favourable long-term patency rates 
179 reported in many series, • - including the only size- 
able, prospective, randomised trial to date. 1° 
As would be expected, PTFE performs most reliably 
in the relatively high flow above-knee position in 
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combination with good run-off. Several studies have 
failed to demonstrate a statistically significant superi- 
ority of vein over PTFE under these condi- 
tions. 3'4'7'8'11-13 This has led numerous authors to 
advocate a policy of preferential use of PTFE for 
above-knee grafting on the basis that surgery is 
simplified without the need for vein dissection, and 
wound morbidity is decreased. Vein is preserved for 
subsequent secondary procedures for graft revision 
and/or for distal (infrapopliteal) disease progression 
and for coronary artery bypass grafting. 6m-17 Despite 
the controversies, many centres currently follow such 
a polic~ whilst accepting the long-term inferiority of 
prosthetic material. 
There are two further questions relevant to the 
debate. The first relates to the demand for preserva- 
tion of autogenous vein for revision procedures. How 
often is further vein required for secondary surgery 
once a primary above-knee vein graft has been 
performed? The second question relates to the influ- 
ence of graft type in above-knee bypass on the 
ultimate fate of the limb with respect o secondary 
procedures and amputation level following graft 
failure. In answering the first question, we provide 
further data in relation to the second. 
1078-5884/95/060220 + 06$12.00/0 © 1995 W. B. Saunders Company Ltd. 
Femoropopliteal Grafts 221 
At Bristol Royal Infirmar)5 it has remained our 
policy to use vein as first choice graft material for 
above-knee f moropopliteal bypass as it is our impres- 
sion that the long-term patency rates are superior to 
PTFE and the demand for vein for secondary recon- 
struction is low. We report our experience, with 
particular emphasis on graft outcome and ultimate 
fate of the limb. 
Patients and Methods 
Data collected prospectively between 1983 and 1992 
on the Vascular Studies Unit computerised database 
was reviewed. All patients undergoing above-knee 
femoropopliteal bypass were identified. For each 
patient demographic data, indication for surger)~ 
operative details, perioperative morbidit)~ hospital 
stay and 30-day graft patency were recorded. Similar 
details for secondary procedures were also recorded* 
on the database, Graft surveillance was commenced in
1987 for all patients undergoing vein grafts.* Post- 
discharge follow-up data was extracted by case-note 
review for all patients and from the graft surveillance 
records where available. All surviving patients under- 
going PTFE grafting were recalled for Duplex evalua- 
tion as surveillance. (*Was not routine in this group.) 
Indication for surgery was either limb-threatening 
ischaemia or severe disabling claudication as defined 
in the European Consensus Document on Critical Leg 
Ischaemia] 8 Primary 3 year graft patenc~ limb sal- 
vage and patient survival rates were computed by life- 
table analyses and the two graft types compared using 
the log rank test. 
Results 
Not unexpectedl)~ vein was used in 80% of above- 
knee femoropopliteal bypass grafts during the study 
period. A total of 112 reconstructions were performed 
on 109 patients (77 male, 33 female; median age: 68 
years [range: 27-87 years]). Eighty-nine grafts were 
vein and 23 were PTFE. Of the vein grafts, 88 were 
greater saphenous vein (63 in situ, 22 reversed and 
three composite) and one was arm vein. PTFE was 
used where vein was absent or inadequate and in all 
cases a 6 mm unsupported prosthesis was used. Table 
1 fists demographic data and indication for operation 
for the two graft types and shows them to be well 
matched, although the proportion of females in the 
PTFE group was higher. However, there were no 
Table 1. Comparative demographic data, incidence of diabetes and 
indication for operation for the patient groups 
Vein grafts PTFE grafts 
n=89 n=23 
Age (years) 66 (27-87) 71 (41-80)* 
Sex distribution (male : female) 64 : 23 13 : 10t 
Incidence of diabetes (7o) 25 (29) 7 (32):~ 
Indication for surgery 
Claudication (%) 35 (39) 9 (39) § 
Critical ischaemia (7O) 54 (61) 14 (61)§ 
* Values are medians (range). Mann-Whitney U-test : U = 771, p = 0.160. 
t %2= 1.77, dr:l, p>0.2. 
~: Z2= 1.08, df:l, p> 0.2. 
§ Z z = 1.0029, df:l, p > 0.2. 
significant differences between the groups in any of 
the parameters listed according to the Mann-Whitney 
U-test and Z 2 test (Table 1). 
The cumulative 3 year primary patenc)5 limb 
salvage and patient survival rates are shown in Figs 1, 
2 and 3 respectively. Both grafts showed an initial high 
failure rate, with a more constant rate of attrition over 
subsequent years. There was little difference in 
patency rates between vein and PTFE in the first year, 
but thereafter, the performance of PTFE fell behind. 
However, these differences were not significant at 3 
years follow-up, according to the log rank test. In 
addition, there were no statistically significant differ- 
ences between the graft types with respect o limb 
salvage and patient survival at 36 months follow-up. 
At a median follow-up of 64 months (8-116 
months), 28 vein grafts (31%) and 11 PTFE grafts (48%) 
had occluded (Table 2). Of the 28 occluded veins, no 
intervention was undertaken in six (21%) and these 
patients remained with viable limbs. Of the remaining 
22 vein grafts, 13 (46% overall) underwent successful 
revision after occlusion and nine (32%) proceeded to 
amputation. Of the 11 occluded PTFE grafts, only one 
(9%) required no action, four (36%) were revised and 
six (55%) proceeded to amputation. 
Table 3 gives a breakdown of the secondary revision 
procedures for the two groups. Of the 13 occluded 
vein grafts which were revised, seven (with less than 
30 days patency) underwent hrombectomy and a 
local procedure for a technical problem; three grafts 
were revised using PTFE and a further three were 
revised using vein (one redo graft with arm vein, one 
jump graft and one interposition graft, both with 
adequate local saphenous vein). The four secondary 
procedures for occluded PTFE grafts included two 
revisions with PTFE, one with arm vein and one 
thrombectomy. Overall 17 secondary procedures were 
performed, but in only four was vein required and 
local ipsilateral saphenous vein sufficed in two of 
these. 
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Fig. 1. Life table analysis howing 3-year cumulative pr imary patency rates for patients undergoing above-knee femoropopliteal bypass 
with vein or PTFE. Numbers  at risk at the beginning of each period are shown, ( - - )  vein; (.-") PTFE; ( - - - )  S.E. > 10%. 
The overall major amputations following graft Discussion 
occlusions were 11 (12%) in the vein group (includes 
two failed secondary procedures) and six (26%) in the Few series have demonstrated statistical superiority of 
PTFE group. Although this was not a statistically vein over PTFE in the above-knee position, although 
significant difference, with respect to the level of the trends are certainly in favour of vein. There is not 
amputation, there were significantly more above-knee one study published to date in which PTFE actually 
amputations after failed PTFE. Only 20% of amputa- surpasses vein at any infrainguinal site in terms of 
tions in the vein group were above-knee (remainder graft patencyJ 9Although no centre has used their data 
below-knee) as against 83% of amputations in the to claim an advantage for PTFE, what is claimed is 
PTFE group being above-knee (Fisher's exact test: that the results are close enough to justify first-line use 
6 11~ 17 p = 0.034). of PTFE to preserve the vein.' - This approach 
89 82 81 74 69 65 45 36 35 34 34 28 28 
23 19 19 17 17 16 16 15 12 9 9 8 8 l°°Fi 
9oF!_  
................................................... 
F _ . . . . . . . . . . . . . . .  6op- 
Log-  rank  tes tp  > 0.2 
40 
, I , I , ] , I , I , I , I ~ I , i ,  I ,  ] , I , I ~ I ~ I , I , I , I , I , 
3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 
Months  
Fig. 2. Life table analysis howing 3-year cumulative l imb salvage rates for patients undergoing above-knee femoropopliteal bypass with 
vein or PTFE. Numbers  at risk at the beginning of each period are shown, ( - - )  vein; (...-) PTFE; ( - -  -) s.E. > 10%. 
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Fig. 3. Life table analysis showing 3-year cumulative patient survival rates for patients undergoing above-knee femoropopliteal bypass with 
vein or PTFE. Numbers at risk at the beginning of each period are shown, (--)  vein; (....) PTFE; (---)  S.E. > 10%. 
Tab le  2. Gra f t  patency  at  a med ian  o f  64 months  fo l low-up  and  
outcome a f ter  fa i lu re  
Vein PTFE 
Occluded grafts 28 (31%) 11 (48%) 
Outcome 
No action 6 (21%) 1 (9%) 
Amputation 9 (32%) 6 (55%) 
Revised* 13 (46%) 4 (36%) 
* See Table 3 for further details. 
assumes that a second procedure will be required. No 
comments are forthcoming as to the difficulties 
involved in dissecting vein from scarred tissues for a 
revision procedure. However, accepting that this 
policy is currently practised, just how great is the 
demand for vein for secondary procedures or for 
coronary bypass? We are not aware of any previous 
work on this aspect of the debate. 
This study was not intended to be yet another 
comparative audit on graft material for above-knee 
femoropopliteal bypass. Indeed, our policy of prefer- 
Tab le  3. Breakdown o f  secondary  rev is ion  procedures  fo r  the  two 
gra f t  types  
Procedure Vein PTFE 
Thrombectomy + 7 1 
local procedure 
Revised with PTFE 3 2 
Revised with vein 3* It 
* One arm vein 
One jump graft ~ using local ong saphenous vein. 
One interposition graft J t'One arm vein. 
ential use of vein in this context makes comparison 
risky as the PTFE cohort was very small  especially 
when considering longer follow-up intervals (five 
patients at 3-year follow-up). This is exactly the 
situation which Michaels cautioned against in his 
comprehensive meta-analysis of the literature on this 
subject) 9 He discussed the limitations of drawing 
meaningful conclusions from studies of non- 
standardised series, most of which were non-random- 
ised and retrospective. However, in order to justify 
our policy of preferential vein utilisation and to 
answer the questions posed at the outset, we must 
demonstrate that our experience with above-knee 
bypass grafting concurs with contemporary practice. 
The 3-year patency rates of 70% for vein and 49% for 
PTFE are in line with other series, particularly 
Michaels' meta-analysis n which the equivalent pri- 
mary patencies at 5 years were 62% and 43% respec- 
tively. 19 The lack of statistical significance in patency 
rates between vein and PTFE is also in agreement with 
published data, as are the discrepancies between the 
graft types illustrated on the survival curves (Figs 1, 2 
and 3). 3"4'7'8'11-13'20 
The demand for vein for secondary procedures is 
low (less than 4% in this series overall). Primary use of 
vein for above-knee grafting does not obviate a 
secondary procedure with further vein, obtained 
either locally or from a distant site. In our experience, 
the need to preserve the long saphenous vein is 
unfounded. The favourable long-term patency rates 
for vein in the above-knee position limits the number 
of patients presenting with a failed graft.' In addition, 
the decreased 5-year survival of these patients due to 
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systemic omplications of atherosclerosis reduces the 
potential numbers surviving long enough to have 
problems with their vein graft. Moreover, use of 
saphenous vein for an above-knee graft potentially 
preserves enough calf vein for a secondary procedure 
such as a jump graft for distal disease progression, and 
with increasing experience from graft surveillance 
programmes more "at risk" grafts will be identified 
before outright failure enabling remedial measures 
(including endovascular procedures) to be under- 
taken, requiring less secondary vein utilisation. 
Finally, groups undergoing above-knee grafting will 
contain relatively more claudicants with disease 
mainly in the superficial femoral artery. Failure of a 
graft with sparing of the profunda femoris and 
popliteal arteries potentially leaves a viable, albeit 
ischaemic, limb. In selected cases, avoidance of further 
intervention may be the safest course. In our series, six 
out of the 28 vein graft failures (21%) underwent no 
further surgery and remained with a viable limb. Only 
one of the 11 PTFE graft failures (9%) succeeded with 
a "no action" policy. Although we have no angio- 
graphic evidence, it is possible that these failed PTFE 
grafts carry with them the popliteal circulation (and/ 
or profunda origin) due to the propensity for aggres- 
sive anastomotic intimal hyperplasia, particularly 
distally. It has been proposed that this is due to the 
compliance mismatch between artery and prosthesis 
causing local flow disturbancesY By contrast, at least 
half the cases of vein graft failure are secondary to 
intra-graft stenoses. 22The graft, in occluding, pre- 
sumably spares native popliteal artery at the anasto- 
mosis and beyond from hyperplastic nvolvement. In
addition, the increased incidence of infection in 
association with prosthetic grafts may adversely influ- 
ence the native circulation in the vicinity of 
anastomoses. 23 
In auditing our experience, we have produced 
further data to support the findings of John et aI. 
(1993) 2° regarding the influence of graft type on the 
ultimate fate of the limb following failure in the above- 
knee position. We have not demonstrated a sig- 
nificantly higher rate of secondary graft revision 
amongst those with occluded PTFE grafts: four out of 
23 (17%) as against 13 out of 89 vein grafts (15%). 
However, the major amputation rate following failure 
of a PTFE graft is more than twice that following vein 
graft failure (26% vs. 12%). The incidence of above- 
knee amputations following failed prosthetic grafting 
is highly significant and agrees with the report of 
Dardik et al. (1982) 24 claim that failed infrainguinal 
bypass increases the risk of converting a potential 
below-knee amputation toa more proximal level, thus 
sacrificing the all-important knee joint. 
The argument in favour of preserving vein for 
coronary grafting no longer holds merit. Popularisa- 
tion of coronary grafting with the internal mammary 
artery has reduced demand for saphenous vein. In 
addition, preservation of vein only holds true for the 
second leg and relatively few patients undergo bilat- 
eral peripheral bypass. Moreover, very few vascular 
patients actually proceed to coronary bypass and 
conversel)~ in large cohorts of cardiac bypass patients 
very small proportions have inadequate saphenous 
vein due to prior peripheral bypass (0.4% in Sterpetti's 
series12).25 
In summar)~ we feel that preferential use of vein for 
above-knee f moropopliteal bypass is justified and far 
outweighs any short-term benefits associated with use 
of PTFE, despite the limitations of a retrospective, 
non-randomised study. In our series, vein grafts 
tended to be more durable and the demand for further 
vein for secondary bypasswas low. In the event of 
graft failure, the amputation rate in the PTFE group 
was higher and significantly so at the above-knee 
level, thus sacrificing the knee joint and increasing the 
costs of rehabilitation. The consequences of graft 
failure were less disastrous in the vein group as 
evidenced by the superior limb viability with no 
intervention despite an occluded graft. To finally settle 
the controversy a large, well-controlled, prospective, 
randomised trial is still required, 19 from which further 
data regarding patterns of disease progression and 
natural history of above-knee atherosclerosis will be 
forthcoming. Such a trial is underway in America, but 
results are not anticipated for some years yet. 26 
We feel that the long-term benefits of using vein 
outweigh the intra-operative simplicity of using PTFE, 
which as first-choice graft material may be positively 
detrimental with respect o the ultimate fate of the 
limb in the event of graft failure. 
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